NephroSant Features QSant, the first urine test for kidney transplant rejection, at Biotech Showcase Digital 2022

SAN FRANCISCO: SAN FRANCISCO, Jan. 3, 2022 /PRNewswire/ -- NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that it will present a company overview at the upcoming Biotech Showcase...

Click to view original post